BioGenes: generic CHO HCP assays cut cost of process dev

By Gareth Macdonald

- Last updated on GMT

Elisas do lots
Elisas do lots

Related tags Elisa

BioGenes says a new panel of generic host cell protein (HCP) assays can help biopharmas save costs during process development.

Like other HCP assays the new CHO360 HCP enzyme-Linked immunosorbent assay (Elisa) panel is designed to determine whether or not biopharmaceuticals are contaminated with proteins derived from the Chinese hamster ovary (CHO) cells in which they are produced.

The difference with the new BioGenes technology is that it consists of a panel of four assays and is capable of detecting - what the firm claims is - the ‘broadest possible’ range of CHO antigens of any test currently on the market.

Spokeswoman Dagmar Schwertner-Knoll told that: “Scientists can use the CHO360 ELISA panel during process development rather and then select the most appropriate kit rather than creating a bespoke assay, which is expensive.”

Schwertner-Knoll explained that BioGenes created the CHO360 HCP Elisa panel by immunising rabbits and goats with proteins from a non-transfected HCP cell lines and then collecting the resulting antibodies.

She added that all four assays have a lower limit of detection (LOD) between 0.5–1 ng/ml and a lower limit of quantification (LOQ) is 2–3 ng/ml with a working range between 2–100 ng/ml, meaning they can be used to detect very small amount of CHO proteins.

Schwertner-Knoll acknowledged that later stage clinical development and commercial production require specific assays tailored to individual production process, but stressed that the idea behind BioGenes’ new tech is to help developers get to that point.

“There are many different opinions on when during the development process bespoke HCP assays are needed but most authorities – including the US Food and Drug Administration (FDA) – require them when the biopharmaceutical in question enters PhIII clinical trials.”

Berlin, Germany-based BioGenes plans to market the new assay panel to both biopharma companies and the contract manufacturing organisations they work with.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers